Lymphopenia Assessment in Stage III Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Proton or Photon Radiation Therapy
JournalInternational Journal of Radiation Oncology - Biology - Physics
MetadataShow full item record
AbstractThe degree of lymphopenia has been linked with negative impact on outcomes in patients undergoing radiation therapy (RT) for stage III non-small cell lung cancer (NSCLC). Proton therapy, by virtue of reducing integral dose, can possibly help mitigate risk of lymphopenia as demonstrated in patients with glioblastoma and esophageal cancer. This study sought to analyze the effects of intensity modulated proton therapy (IMPT) in limiting degree of lymphopenia in patients with stage III NSCLC when compared to those treated with photon-based volumetric-modulated arc therapy (VMAT).
Rights/TermsCopyright © 2021 Published by Elsevier Inc.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/18473